Document is current
Any future updates will be listed below
-
Authors
Walter, Romina J.
Sonnentag, Steffen J.
Munoz-Sagredo, Leonel
Merkel, Melanie
Richert, Ludovic
Bunert, Felix
Heneka, Yvonne M.
Loustau, Thomas
Hodder, Michael
Ridgway, Rachel A. https://orcid.org/0000-0003-0198-8244
Sansom, Owen J. https://orcid.org/0000-0001-9540-3010
Mely, Yves
Rothbauer, Ulrich
Schmitt, Mark
Orian-Rousseau, Véronique https://orcid.org/0000-0003-2939-9257
-
Funding
Funding for this research was provided by:
Cancer Research UK (A17196, A21139, A21139, A17196)
- License Information
-
More Information
Article History
Received: 6 July 2021
Revised: 17 January 2022
Accepted: 4 February 2022
First Online: 21 February 2022
Competing interests
: VO-R is an advisory board member and has shares in amcure. amcure develops a CD44v6 peptide. CD44v6 is not the subject of this study and the peptide was not used in this paper.
